By R. Lewis Dark, from the Volume XXIV, No. 10 – July 17, 2017 issue
Here’s an update on Theranos, the troubled lab company that is struggling to stay alive. Once again, reporter John Carreyrou of The Wall Street Journal scooped his peers by reporting that Theranos has listed its corporate offices for lease. For lab companies shopping for office space in Palo Alto, Calif., Theranos has listed its 116,172 square
By Joseph Burns, from the Volume XXIV, No. 9 – June 26, 2017 issue
CEO SUMMARY: In Dallas, the relatively short-lived lab company known as Med Fusion has a new owner. After seven years, the lab partnership of Baylor Scott and White, US Oncology Network, Texas Oncology, and Pathologists Bio-Medical Laboratories decided to sell their ownership stakes to Quest Diagnostics. The sale comes despite $100 million of capital and
By Joseph Burns, from the Volume XXIII No. 4 – March 21, 2016 issue
CEO SUMMARY: UnitedHealthcare directly tackled the issue of out-of-network labs waiving or capping copayments, coinsurance and deductibles that are to be paid by patients. In a network bulletin this month, UHC said that such arrangements may violate federal law and could lead to state insurance department investigations into false claims. In the same bulletin to
By Robert Michel, from the Volume XXII, NO. 18 - December 28, 2015 issue
CEO SUMMARY: During 2015, two stories captured the full attention of most pathologists and clinical lab managers. One was how CMS intends to gather lab price market data as mandated by PAMA. The other was the continued efforts by the FDA to move ahead on proposed guidance for regulation of LDTs. However, the full list
By Joseph Burns, from the Volume XXII NO. 10 - July 13, 2015 issue
OVERWHELMED WITH REQUESTS TO PAY for new genetic tests, health insurers, particularly smaller and regional insurers, find it easier to simply deny payment for such tests.
By Joseph Burns, from the Volume XIX No. 9 - June 25, 2012 issue
CEO SUMMARY: Based in Brentwood, Tennessee, Regional Diagnostic Laboratories (RDX) says it wants to purchase the laboratory outreach programs of nonprofit community hospitals. RDX is a partnership with Warburg Pincus, a New York investment company. It is a credible buyer and has $250 million available to fund these acquisitions. Brian Carr, RDX’s CEO, predicts that
By Robert Michel, from the Volume XIV No. 6 - April 23, 2007 issue
CEO SUMMARY: As genomic medicine advances, researchers into various diseases quickly recognize the need to incorporate molecular pathologists onto their teams. In Grand Rapids, Michigan, a large integrated health system and a private research institute have come together to jointly fund a state-of-the-art molecular pathology laboratory. The twin goals are to advance research and create
By Robert Michel, from the Volume IX No. 3 - February 18, 2002 issue
CEO SUMMARY: At a time when lab testing meant routine assays performed within a few miles of the collection, Albert L. Nichols, M.D. envisioned a centralized national laboratory devoted to performing specialized, highly-complex testing to clinicians everywhere. Not only did his vision become the reality of the lab we know today as Nichols Institute, but
By Robert Michel, from the Volume VII No. 7 - May 8, 2000 issue
CEO SUMMARY: Laboratory Corporation of America is serving notice that it intends to increase its competitive presence in California, the largest market for diagnostic testing in the United States. It recently signed agreements to purchase two respected independent laboratory companies, one in Los Angeles, the other in San Diego. Owners of both acquired companies had
